La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Pop Culture Gr a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Pop Culture Gr..

Pop Culture Gr (NASDAQ:CPOP) Azioni, Catena delle Opzioni

Pop Culture Gr

Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.

JP Morgan analyst Seth Seifman maintains Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) with a Underweight and raises the price target from $115 to $122.

News

Price Target

Analyst Ratings

JP Morgan Maintains Underweight on Booz Allen Hamilton, Raises Price Target to $122

Macro Economic Events

Politics

Global

Economics

General

Reuters Cites Brazil's Lula Saying Hope Trump Will Think About Brazil's Importance, Negotiate Tariffs

Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) on Monday to <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">develop up to 12 medicines</a>.
These agreements will add significant value to Hengrui&#8217;s globalization strategy and provide GSK with significant new growth opportunities beyond 2031.
The programs were selected to complement GSK&#8217;s extensive Respiratory, Immunology &amp; Inflammation (RI&amp;I) and Oncology pipeline.
Also Read: <a href="https://www.benzinga.com/news/fda/25/07/46607015/gsks-blood-cancer-drug-review-extended-as-fda-seeks-more-data" target="_blank" rel="noreferrer noopener">GSK&#8217;s Blood Cancer Drug Review Extended As FDA Seeks More Data</a>
GSK will pay $500 million in upfront fees across the agreements.
The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan region) for (HRS-9821) in clinical development for chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46651745/hengrui-pharma-and-gsk-enter-agreements-to-develop-up-to-12-innovative-medicines-across-respirator" rel="noreferrer noopener">irrespective of background therapy</a>.
HRS-9821 has demonstrated potent PDE3 and PDE4 inhibition, leading to increased bronchodilation and anti-inflammatory effects in early clinical and preclinical studies.
In addition, HRS-9821 provides the opportunity for a convenient dry-powder inhaler (DPI) formulation that strategically fits GSK&#8217;s established inhaled portfolio.
The agreements also include a scaled collaboration to generate up to 11 programs in addition to HRS-9821, each with its financial structure.
Hengrui Pharma will lead the development of these programs up to completion of phase I trials. Patients outside of China will participate.
GSK may commercialize each program, except for those in China, Hong Kong, Macau, and Taiwan, at the end of phase 1.
Tony Wood, Chief Scientific Officer, GSK, said: &#8220;This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact.&#8221;
The collaboration enables scale and speed to proof-of-concept to develop up to 11 additional innovative medicines.&#8221;
If all programs are optioned and all milestones are achieved, the potential total value of future success-based development, regulatory, and commercial milestone payments to Hengrui Pharma is approximately $12 billion.
In addition, Hengrui Pharma will be eligible to receive tiered royalties on global product net sales (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan region).
In March, Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Hengrui Pharma entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44477157/merck-partners-with-hengrui-pharma-in-177-billion-deal-for-cardiovascular-treatment" rel="noreferrer noopener">Phase 2 trial in China</a>.
Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44470230/merck-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoprotein-a-inhibi" rel="noreferrer noopener">Greater China region</a>.
Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments associated with certain development, regulatory, and commercial milestones up to $1.77 billion and royalties on net sales of HRS-5346 if approved.
Price Action: GSK stock is down 0.74% at $37.69 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46657204/sharplink-gaming-stock-climbs-over-5-in-monday-pre-market-whats-going-on" target="_blank" rel="noreferrer noopener">SharpLink Gaming Stock Climbs Over 5% In Monday Pre-Market: What&#8217;s Going On?</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Health Care

Contracts

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

Trading Ideas

PFSA

Profusa Shares Halted On Circuit Breaker To The Upside, Stock Now Up 66.1%

Guidance

Fomento Economico Mexicano S.A.B. De C.V.

Reuters Cites Mexico's FEMSA CFO Saying Sustained Weakness In Traffic In Mexico Is The Focal Point For The Co's Commercial Initiatives In Second Half Of The Year

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 20 years by 3.25% on an annualized basis producing an average annual return of 11.8%. Currently, Agnico Eagle Mines has a market capitalization of $63.24 billion. 
Buying $1000 In AEM: If an investor had bought $1000 of AEM stock 20 years ago, it would be worth $9,328.30 today based on a price of $125.79 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753716623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

On July 28, 2025, Profusa, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Ascent Partners Fund LLC (the "Purchaser"). Pursuant to the terms and conditions set forth in the Purchase Agreement, the Company may, from time to time and at its discretion, issue and sell to the Purchaser shares of its common stock (the "Purchased Securities") for an aggregate purchase price of up to $100,000,000 (the "Maximum Aggregate Purchase Price"), subject to certain limitations and conditions described below.
&nbsp;
Under the Purchase Agreement, the Company may deliver advance notices (each, an "Advance Notice") to the Purchaser to request the purchase of shares of common stock, with each closing (a "Closing") to occur on a trading day following the end of a 10 or fewer trading day valuation period commencing on the trading date immediately following the delivery of the Advance Notice, or as determined by the Purchaser. The purchase price per share at each Closing will be equal to 97% of the lowest volume-weighted average price ("VWAP") of the Company's common stock during the applicable valuation period, subject to a floor price and other adjustments as set forth in the Purchase Agreement. The maximum purchase price at any single Closing is limited to the lower of (a) $5,000,000 or (b) 100% of the average daily traded value of the common stock for the five trading days immediately preceding such Closing.
&nbsp;
The Purchase Agreement contains certain limitations, including that the aggregate number of shares issued under the Purchase Agreement may not exceed the number of shares registered under the applicable registration statement or the exchange cap (generally 19.9% of the Company's outstanding common stock as of the effective date), unless stockholder approval is obtained or as otherwise permitted by the rules of the principal trading market. In addition, the Purchaser's beneficial ownership of the Company's common stock is limited to 9.99% of the outstanding shares immediately after giving effect to any issuance.
&nbsp;
The Company is required to deliver the Purchased Securities as DWAC shares to the Purchaser on the date that it delivers the applicable Advance Notice. If the Company fails to timely deliver the shares, the Purchaser may, among other remedies, deem the Advance Notice rescinded or require the Company to pay certain cover costs. The Purchaser may resell the Purchased Securities during the valuation period, and the Company is obligated to return any surplus shares if the Maximum Aggregate Purchase Price is exceeded.
&nbsp;
The Purchase Agreement also provides for the issuance of a warrant to the Purchaser for the purchase of 900,000 shares of common stock, and includes a Registration Rights Agreement, Lock-Up Agreements from the Company's officers and directors, and a Transfer Agent Instruction Letter. The Company is required to reserve sufficient shares of common stock to satisfy its obligations under the Purchase Agreement and to maintain the listing of its common stock on its principal trading market.
&nbsp;
The Company has made customary representations and warranties, including as to its organization, authorization, capitalization, compliance with laws, and the absence of material adverse effects, among others. The Purchaser has also made customary representations, including as to its status as an accredited investor and its investment intent.
&nbsp;
The Purchase Agreement contains covenants restricting the Company from entering into certain equity line or at-the-market transactions, exchange transactions, or related party transactions without the Purchaser's consent, and requires the Company to maintain current public information, timely file required reports, and make certain public disclosures regarding the transaction. The Company is also required to indemnify the Purchaser and its affiliates for certain losses arising out of the transaction.
&nbsp;
The proceeds from the sale of the Purchased Securities are to be used exclusively for the purchase of Bitcoin (which may be used for repayment of indebtedness), provided the Company's cash balance on any Closing Date exceeds $5,000,000. If the cash balance is less than $5,000,000, proceeds must first be used to bring the cash balance to that amount, with the remainder used to purchase Bitcoin. The Company is prohibited from using proceeds for executive compensation, distributions, or repayment of indebtedness to security holders.
&nbsp;

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Financing

Markets

UPDATE: On July 28, 2025, Profusa Entered New $100M Stock Purchase Agreement With Ascent Partners To Fund Bitcoin Acquisitions

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock is trading upwards on Monday, akin to its semiconductor peers. This coincides with reports indicating the United States <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46661640/us-holds-back-tech-export-crackdown-to-support-trump-xi-talks" rel="noreferrer noopener">paused new restrictions</a> on tech exports to China to avoid disrupting trade talks and support President Donald Trump&#8217;s effort to meet with Chinese President Xi Jinping later this year.
According to the report, which cited current and former U.S. officials, the Commerce Department&#8217;s Bureau of Industry and Security received instructions in recent months to delay strict enforcement of export controls on China.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46463670/supermicro-launches-new-ai-servers-with-intel-xeon-6-chips" rel="noreferrer noopener">Supermicro Launches New AI Servers With Intel Xeon 6 Chips</a>
This policy shift comes as top U.S. and Chinese economic officials prepare to launch high-level trade discussions in Stockholm aimed at resolving long-standing disputes.
The AI server specialist has seen a remarkable surge in its valuation this year, boasting a year-to-date gain exceeding 90%, with a notable 56% increase over the past three months. This robust performance is largely attributed to significant capital expenditure by leading technology companies on their artificial intelligence initiatives, fueling demand for Super Micro&#8217;s specialized server solutions.
In a related development, Super Micro partner Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) announced that its subsidiary, US Data Centers, filed a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46655864/digi-power-x-subsidiary-us-data-centers-inc-files-provisional-patent-for-arms-200-modular-ai-data-" rel="noreferrer noopener">provisional utility patent</a> for the ARMS 200 platform with the U.S. Patent Office.
The ARMS 200 represents a Tier 3-certified modular data center, developed in collaboration with Super Micro, and engineered to support an impressive density of up to 256 Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) B200/B300 GPUs per pod.
Digi Power X intends to scale this platform to 40 MW at its Alabama facility, designed to power over 10,000 Nvidia GPUs for intensive AI workloads.
The initial deployment of this advanced infrastructure is slated for the fourth quarter of 2025. It is worth noting that Digi Power X <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46471195/digi-power-x-stock-jumps-after-deal-with-supermicro-to-roll-out-nvidia-powered-ai-systems" rel="noreferrer noopener">shares surged</a> over 14% on July 17 following the announcement of a purchase order with Super Micro for Nvidia B200-powered systems, intended to underpin its Tier 3 AI infrastructure.
Despite these positive developments, Super Micro has faced <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46427157/why-is-supermicro-stock-surging-on-tuesday" rel="noreferrer noopener">increased regulatory scrutiny</a> concerning its internal financing controls. This heightened oversight followed the resignation of its independent auditor last October, an event that led to delays in the company&#8217;s financial filings.
Furthermore, persistent tariff uncertainties have compelled Super Micro to defer certain orders and revise its fiscal year revenue forecast downwards, narrowing the range to $21.8–$22.6 billion from the previously projected $23.5–$25 billion.
Price Action: SMCI shares were trading higher by 8.23% to $58.97 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46475029/semiconductor-stocks-react-to-key-policies-and-earnings" target="_blank" rel="noreferrer noopener">Semiconductor Stocks React To Key Policies And Earnings</a></li>
</ul>
Photo via Shutterstock

Movers

Tech

DGXX

NVDA

SMCI

What's Going On With Super Micro Stock On Monday?

Comprehensive offering will enable public safety agencies to adhere to new federal reporting requirements
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tylertech.com%2F&amp;esheet=54297529&amp;newsitemid=20250728949755&amp;lan=en-US&amp;anchor=Tyler+Technologies%2C+Inc.&amp;index=1&amp;md5=520d1dc442ffbffc1826bd2264c8eb06">Tyler Technologies, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) announced today that it has acquired Emergency Networking, Inc., a software-as-a-service (SaaS) company specializing in cloud-native software for fire departments and emergency medical services (EMS) agencies.
Tyler's acquisition of Emergency Networking strengthens Tyler's comprehensive public safety suite at a critical time. By January 1, 2026, all fire and EMS departments nationwide must move from the National Fire Incident Reporting System (NFIRS) to the National Emergency Response Information System (NERIS). Emergency Networking is one of the first fire records reporting solutions to meet and submit to the new NERIS compliance requirements.
With Emergency Networking's expertise in the fire and EMS industry, Tyler now has the most comprehensive suite of solutions for public safety agencies, from law enforcement to first responders to EMS agencies.

Tyler Technologies Acquires Emergency Networking To Support Nationwide Shift To NERIS Compliance By 2026; No Financial Terms Disclosed

Think you and your spouse are crushing it financially? You might be doing better than you think — or not even close — depending on how you measure.
According to personal finance site <a href="https://www.financialsamurai.com/the-average-net-worth-for-the-above-average-married-couple/">Financial Samurai</a>, there's a big difference between being typical and being intentional. The site's benchmark for the "above-average person" doesn't come from ambition or vibes — it's built on clear expectations.
To be considered above average, you're expected to graduate from college, which only about 36% of Americans do. You're expected to work diligently, save consistently, take full advantage of retirement accounts like 401(k)s or IRAs, track your finances, invest regularly, live within your means, and expect nothing from your parents, spouse, or the government.
Don't Miss:
<ul class="wp-block-list">
<li>Be part of the breakthrough that could replace plastic as we know it—<a href="https://www.benzinga.com/money/timeplast-advertorial">invest in Timeplast before the July 31st deadline and help revolutionize a $1.3T industry.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
In short, if you're living like a C-student but expecting an A-lifestyle, Financial Samurai would not put you in the above-average category.
Based on this profile, an above-average individual is projected to reach a net worth of around $660,250 by age 45. But what if there are two of you?
<h2 class="wp-block-heading">Defining the Above-Average Couple</h2>
Some might assume that two financially savvy individuals should simply double their solo benchmarks and call it a day. But Financial Samurai recommends a more conservative approach by using a 1.7x multiplier instead of 2. This accounts for the financial efficiencies that couples often enjoy when it comes to housing, utilities, food, insurance, and transportation.
By applying this method, an above-average couple in their mid-40s should aim for a combined net worth of roughly $1.12 million.
That target represents a couple who's aligned on money, disciplined with spending, and working toward common long-term goals. This isn't a figure reserved for doctors and tech executives — it's within reach for many dual-income households that save and invest consistently over time.
Trending: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a>
<h2 class="wp-block-heading">Where Does That Put You Nationally?</h2>
The Federal Reserve's most recent <a href="https://www.federalreserve.gov/publications/files/2023-report-economic-well-being-us-households-202405.pdf">Survey of Consumer Finances</a> reports that the median net worth for U.S. households is around $192,900. That means half of American households are below that figure. The average net worth, skewed by ultra-high earners, is higher — roughly $1.06 million.
If you're aiming for the top 10% of households, the bar is significantly higher. To join the top decile in America, you need a <a href="https://www.benzinga.com/personal-finance/24/12/42675663/think-youre-richer-than-your-peers-heres-the-net-worth-you-need-to-rank-among-the-top-10-for-your-age">household net worth</a> of at least $1.92 million. To break into the top 5%, you'll need around $3.78 million. The top 1% of households starts at approximately $13.7 million.
By comparison, a Financial Samurai–style above-average couple may not be in the top 10% just yet — but they're still well ahead of most American households.
<h2 class="wp-block-heading">Why Couples Have the Advantage</h2>
Financially aligned couples often benefit from the natural efficiencies of sharing a household. Two people working together toward shared savings and investing goals can make faster progress than individuals operating separately. When couples reduce overlapping costs and increase financial communication, they compound their efforts — both literally and figuratively.
<a href="https://www.benzinga.com/personal-finance/25/02/43447772/can-you-guess-what-it-takes-to-be-a-rich-household-heres-the-income-youll-need-to-be-in-the-top-1">Income alone</a> isn't what separates average from above-average. Behavior, consistency, and clarity do. Financial Samurai emphasizes the importance of tracking net worth regularly, resisting lifestyle creep, and prioritizing long-term goals over short-term indulgences.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
If your household net worth is between $500,000 and $1 million, you're likely ahead of the national average but not yet in the top 10%. If you've crossed the $1.9 million threshold in your 40s or 50s, you're solidly within the wealthiest tier of U.S. households.
<h2 class="wp-block-heading">Graded on a Curve? Not Quite</h2>
"Above average" sounds like something you'd see on a report card — but real-life finances aren't graded on a curve. One couple's $1.2 million might mean financial freedom. For another, it barely covers the mortgage and daycare.
Some want to upgrade their home. Others want to backpack through Europe. The point is: there's no universal benchmark.
If you're living below your means, investing in a way that fits your risk level, and <a href="https://www.benzinga.com/money/smartasset">consistently working toward goals</a> that matter to you, you're probably doing just fine.
There's no gold star for hitting a number. The only standard that counts is the one you set together.
Read Next: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Image: Shutterstock

Personal Finance

Are You an 'Above‑Average' Couple? Here's The Net Worth You Need to Be Richer Than 90% of Households

CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) on Monday shared 32-week data from the Extension phase of its Phase 2b RewinD-LB trial evaluating oral neflamapimod in patients with <a href="https://www.benzinga.com/general/health-care">Dementia with Lewy Bodies (DLB)</a>.
The initial 16-week, randomized, double-blind, placebo-controlled portion of the study included 159 DLB patients and was followed by a 32-week Extension phase in which all participants received neflamapimod (40mg TID).
Results from the Extension phase showed that neflamapimod continued to slow disease progression and impacted a key plasma marker of neurodegeneration in DLB patients.
Also Read: <a href="https://www.benzinga.com/25/03/44312894/cervomeds-dementia-studys-16-week-data-compelling-enough-to-move-from-sidelines-analyst-says" target="_blank" rel="noreferrer noopener">CervoMed&#8217;s Dementia Study&#8217;s 16-Week Data &#8216;Compelling Enough To Move From Sidelines&#8217; Analyst Says</a>
New Data: 32-Week Results from the Extension Phase of the Phase 2b RewinD-LB Trial1
<ul class="wp-block-list">
<li>An older batch of neflamapimod capsules was utilized, which were associated with plasma exposures below the expected and targeted range, while capsules from a new batch of neflamapimod were associated with achieving target plasma concentrations and observing statistically <a href="https://www.benzinga.com/pressreleases/25/07/g46655323/cervomed-announces-32-week-data-from-rewind-lb-trial-extension-phase-showing-neflamapimods-sustain" target="_blank" rel="noreferrer noopener">significant clinical benefit</a>.</li>
<li>Patients treated with New Capsules demonstrated statistically significant slowed disease progression compared to patients treated with Old Capsules.</li>
<li>Even greater risk reductions were observed in patients with ptau181 &lt; 2.2 pg/mL – the threshold CervoMed believes is the optimal ptau181 threshold for evaluating the presence of AD co-pathology in patients with DLB.</li>
<li>Researchers also presented data evaluating different cut-off levels of ptau181 based on the 32-week results and assessed the correlation between ptau181 and ptau217, a validated biomarker for AD.</li>
</ul>
New Data: Reduction in Plasma Levels of Glial Fibrillary Acidic Protein at Week 32 of Extension Phase
<ul class="wp-block-list">
<li>At Week 32 of the Extension phase, there was a statistically significant reduction from baseline in GFAP plasma levels in patients who received New Capsules for all 32 weeks, with a mean change of -18.4±4.0 pg/mL in all participants (N=107) and -21.2±4.4 pg/mL in participants with screening plasma ptau181 below 2.2 pg/mL (N=91).</li>
<li>Placebo recipients in the initial, double-blind phase of the trial had a mean increase from baseline to Week 16 of +1.1±3.0 pg/mL in all participants (N=74) and +1.1±3.3 pg/mL in the subset with screening plasma ptau181 below 2.2 pg/mL (N=65).</li>
</ul>
Both Old and New Capsules demonstrated comparable tolerability profiles, and no new safety signals were identified during the Extension phase of the trial.
During the first 16 weeks of the Extension phase, a lower incidence of falls was seen in participants with screening ptau181 &lt; 2.2 pg/mL who received New Capsules of neflamapimod as compared to participants who received either Old Capsules or placebo (vs. Old Capsules, p=0.025; vs. placebo, p=0.007).
Price Action: CRVO stock is up 29.4% at $11.62 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46657104/mara-cleanspark-avoided-the-ai-hype-and-thats-their-superpower" target="_blank" rel="noreferrer noopener">MARA, CleanSpark Avoided The AI Hype—And That&#8217;s Their Superpower</a></li>
</ul>
Image: Shutterstock

CRVO

CervoMed's Dementia Data Show Slowed Disease Progression

NITO

N2OFF Says On July 25, Enters Amendment To Purchase Agreement With YA II PN; Investor Commits To Advance $3M To N2OFF, And Investor Agree To Revise Promissory Notes

SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. ("Opendoor" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>), a leading e-commerce platform for residential real estate transactions, today announced that it intends to convene and then adjourn the Special Meeting of Stockholders (the "Special Meeting") scheduled to occur at 9:30 a.m. Pacific Time, on Monday, July 28, 2025 until August 27, 2025. No other business will be conducted at the Special Meeting.
The Special Meeting was being held to consider two proposals related to a discretionary reverse stock split of the Company's common stock. Approval of the proposals does not mean that a reverse stock split would occur. Rather, an approval would provide the Company's Board of Directors with an option to pursue a reverse stock split only if the Board believes it is in the best interests of Opendoor and its stockholders, which includes seeking to ensure that Opendoor remains listed on Nasdaq.
As previously disclosed, the Company received notice from Nasdaq in May that it had failed to comply with Nasdaq listing rules because the closing price of the Company's common stock was below $1.00 per share for 30 consecutive business days.
For Opendoor to be back in compliance with Nasdaq listing rules, the closing price of Opendoor's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days by November 24, 2025, and Nasdaq, in its sole discretion, can extend this minimum 10-day trading period. As of today, Nasdaq has not notified the Company that it has regained compliance with Nasdaq listing requirements.
In light of the recent volatility in the trading of Opendoor's common stock and the impact on its trading price, the Board believes it is in the best interests of Opendoor and its stockholders to adjourn the Special Meeting today to allow for additional time to assess market conditions and the Company's stock price before holding the Special Meeting.
The Special Meeting will be adjourned until 9:30 a.m. Pacific Time on August 27, 2025. It will continue to be held online at <a href="http://www.virtualshareholdermeeting.com/OPEN2025SM">www.virtualshareholdermeeting.com/OPEN2025SM</a>. For information on how to attend the reconvened Special Meeting online and submit questions during the Special Meeting, please see the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the "SEC") on June 16, 2025 (the "Proxy Statement").
The record date for stockholders entitled to vote at the Special Meeting remains June 4, 2025. During the period of adjournment, the Company will continue to accept stockholder votes and any stockholders who have not yet voted are encouraged to do so. The Company encourages any eligible stockholder that has not yet voted their shares or provided voting instructions to their broker or other record holders to do so promptly. Any stockholders who have already voted or submitted a proxy do not need to take any further action unless they wish to change their vote.
Additional Information and Where to Find It
The Company has, on June 16, 2025, filed a Proxy Statement with the SEC with respect to its solicitation of proxies for the Special Meeting.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY THE COMPANY AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE SOLICITATION.
Investors and security holders may obtain copies of these documents and other documents filed with the SEC by the Company free of charge through the website maintained by the SEC at <a href="http://www.sec.gov/">www.sec.gov</a>. Copies of the documents filed by the Company are also available free of charge by accessing the Company's website at <a href="https://www.globenewswire.com/Tracker?data=smfQXwH-VRSaHCTz5wj0wU93NRllb0R3YkmnycxIUNq6gZuZhNwGhV2ootMScegW7P_1pqN1yAReunfBHoxo_wUhPKQlslmXmrk_RDh1ieM=">www.opendoor.com</a>.

OPEN

Reported Earlier: Opendoor Technologies Intends To Convene And Then Adjourn The Special Meeting Of Stockholders To August 27, 2025

WIIM

RDZN

Roadzen shares are trading lower after the company announced the pricing of a $2.25 million registered direct offer of 1,730,769 shares at $1.30 per share.

TSLA

Tesla shares are trading higher after the company announced a $16.5 billion AI chips deal with Samsung.

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 1.13% on an annualized basis producing an average annual return of 13.4%. Currently, Graphic Packaging Holding has a market capitalization of $7.04 billion. 
Buying $100 In GPK: If an investor had bought $100 of GPK stock 15 years ago, it would be worth $646.92 today based on a price of $23.32 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753715720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Graphic Packaging Holding 15 Years Ago Would Be Worth This Much Today

Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) on Monday reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46655378/enterprise-reports-second-quarter-2025-earnings" rel="noreferrer noopener">second-quarter 2025</a> earnings that beat analyst expectations on earnings per share but missed on revenue, while setting multiple operating volume records across its midstream network.
Enterprise posted earnings of 66 cents per unit, up 3% from 64 cents in the same quarter a year earlier and beating the consensus estimate of 64 cents. However, revenue came in at $11.36 billion, missing analysts&#8217; expectations of $14.19 billion.
Distributable cash flow (DCF) rose 7% year over year to $1.9 billion, providing 1.6 times coverage of the company&#8217;s declared $0.545 per-unit distribution, up 3.8% from a year ago. Enterprise retained $748 million of DCF to reinvest in growth.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46653030/enterprise-products-partners-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" target="_blank" rel="noreferrer noopener">Enterprise Products Partners Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Adjusted cash flow from operations remained steady at $2.1 billion, and for the 12 months ended June 30, stood at $8.6 billion. Enterprise repurchased $110 million worth of common units during the quarter and reported a 12-month payout ratio of 57%.
&#8220;In a seasonally weaker quarter challenged by macroeconomic and commodity headwinds, Enterprise reported solid earnings and cash flow,&#8221; said A. J. &#8220;Jim&#8221; Teague, co-chief executive officer of Enterprise&#8217;s general partner.
<h2 class="wp-block-heading">Operating Records and Segment Highlights</h2>
Despite broader market challenges, the company set five new operating records:
<ul class="wp-block-list">
<li>Natural gas processing inlet volumes: 7.8 billion cubic feet per day (Bcf/d), up 3% year over year</li>
<li>Natural gas pipeline volumes: 20.4 trillion Btus per day (TBtus/d), up 9%</li>
<li>Crude oil pipeline volumes: 2.6 million barrels per day (BPD), a new high</li>
<li>Refined products and petrochemical pipelines: 1.0 million BPD</li>
<li>Total NGL pipeline volumes: 4.6 million BPD, up 5%</li>
</ul>
Gross operating margin rose to $2.5 billion, up from $2.4 billion in the prior year&#8217;s quarter.
<ul class="wp-block-list">
<li>NGL Pipelines &amp; Services held flat at $1.3 billion, with higher pipeline and terminal volumes offsetting lower NGL marketing and Rockies processing margins.</li>
<li>Natural Gas Pipelines &amp; Services surged 42% to $417 million, driven by stronger marketing margins, increased Permian volumes, and higher throughput on the Texas Intrastate System.</li>
<li>Crude Oil Pipelines &amp; Services fell to $403 million from $417 million, with lower marine terminal volumes and marketing activity partially offset by lower costs and storage revenues.</li>
<li>Petrochemical &amp; Refined Products slipped to $354 million from $392 million due to weaker octane enhancement margins, though pipeline volumes hit a record.</li>
</ul>
Enterprise reaffirmed that approximately $6 billion in organic growth projects will enter service in the second half of 2025. These include:
<ul class="wp-block-list">
<li>Two new Permian gas processing plants, Mentone West 1 and Orion, boosting processing capacity across the Delaware and Midland Basins to over 4.4 Bcf/d.</li>
<li>Commissioning of the Neches River Terminal in mid-July, with a 120,000 BPD ethane refrigeration train now operational.</li>
<li>Frac 14 and the Bahia NGL pipeline, scheduled to come online in Q4.</li>
</ul>
Enterprise invested $1.3 billion in the second quarter of 2025, including $1.2 billion in growth capital and $117 million in sustaining capex.
The company reaffirmed full-year 2025 organic growth capex guidance of $4.0 billion to $4.5 billion and $525 million in sustaining expenditures.
As of June 30, the company had total debt of $33.1 billion and consolidated liquidity of $5.1 billion, including credit capacity and unrestricted cash.
Price Action: EPD shares are trading lower by 1.38% to $31.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/07/46655853/rare-earths-are-the-energy-transitions-hidden-bottleneck-study-shows" target="_blank" rel="noreferrer noopener">Rare Earths Are The Energy Transition&#8217;s Hidden Bottleneck, Study Shows</a></li>
</ul>
Photo by sdf_qwe via Shutterstock

Earnings

Enterprise Products Partners Posts Strong Cash Flow, Reaffirms Capex Plan

IPOs

Figma IPO Price Expected Between $30 And $32 Per Share

Rumors

Watching Samsara; Shares See Volume To The Upside, Traders Circulate Stock Picked As A Buy On Popular Trading Newsletter

Biotechnology firms are increasingly turning to innovative combination therapies to <a href="https://www.benzinga.com/general/biotech">tackle hard-to-treat cancers</a>, with promising results sparking investor interest. AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
The study is evaluating Ampligen (rintatolimod) in combination with AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), in metastatic pancreatic cancer patients with <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noopener">stable disease following FOLFIRINOX treatment</a>.
The DURIPANC study, a collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands, is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion.
As of the mid-year report, 14 subjects had been enrolled in DURIPANC. The primary objective of the study is to determine the clinical benefit rate of the combination therapy; the secondary/exploratory objectives include assessing overall survival (OS), progression-free survival (PFS), and initiating immune monitoring using available tissue biopsies <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46657801/aim-immunotech-reports-positive-mid-year-safety-and-efficacy-data-from-phase-2-study-evaluating-am" rel="noreferrer noopener">and peripheral immune profiling</a>.
Following FOLFIRINOX, maintenance or second-line immunotherapies have historically shown limited survival benefit in comparison trials. Compared to these data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS:
<ul class="wp-block-list">
<li>No significant toxicity, an encouraging safety profile for a post-chemo setting.</li>
<li>Around 21% of patients have progression-free survival (PFS) of over 6 months (3/14), with an additional 21% not yet progressed.</li>
<li>The majority (64%) of eligible patients had an overall survival of over 6 months, which is better than expected in this setting.</li>
</ul>
AIM has developed an intellectual property plan specific to pancreatic cancer that includes a recently issued U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection to Aug. 9, 2039.
AIM Price Action: AIM ImmunoTech shares were up 36.79% at $11.49 at the time of publication on Monday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46657284/palantirs-next-stop-is-200-says-jim-cramer-as-pltr-glides-like-a-knife-through-butter" target="_blank" rel="noreferrer noopener">Palantir&#8217;s Next Stop Is $200, Says Jim Cramer As PLTR Glides &#8216;Like A Knife Through Butter&#8217;</a></li>
</ul>
Photo: jittawit21/Shutterstock

Comments

Pop Culture Gr

Pop Culture Gr (CPOP) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO